CY2016013I2 - Φαρμακευτικες συνθεσεις που περιλαμβανουν βαλσαρτανη και αναστολεις nep - Google Patents

Φαρμακευτικες συνθεσεις που περιλαμβανουν βαλσαρτανη και αναστολεις nep

Info

Publication number
CY2016013I2
CY2016013I2 CY2016013C CY2016013C CY2016013I2 CY 2016013 I2 CY2016013 I2 CY 2016013I2 CY 2016013 C CY2016013 C CY 2016013C CY 2016013 C CY2016013 C CY 2016013C CY 2016013 I2 CY2016013 I2 CY 2016013I2
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
compositions containing
nep inhibitors
containing valsartan
valsartan
Prior art date
Application number
CY2016013C
Other languages
English (en)
Other versions
CY2016013I1 (el
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23373410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2016013(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2016013I1 publication Critical patent/CY2016013I1/el
Publication of CY2016013I2 publication Critical patent/CY2016013I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY2016013C 2002-01-17 2016-05-18 Φαρμακευτικες συνθεσεις που περιλαμβανουν βαλσαρτανη και αναστολεις nep CY2016013I2 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34966002P 2002-01-17 2002-01-17
PCT/EP2003/000415 WO2003059345A1 (en) 2002-01-17 2003-01-16 Pharmaceutical compositions comprising valsartan and nep inhibitors

Publications (2)

Publication Number Publication Date
CY2016013I1 CY2016013I1 (el) 2016-10-05
CY2016013I2 true CY2016013I2 (el) 2016-10-05

Family

ID=23373410

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20071101386T CY1106959T1 (el) 2002-01-17 2007-10-25 Φαρμακευτικες συνθεσεις που περιλαμβανουν βαλσαρτανη και αναστολεις nep
CY2016013C CY2016013I2 (el) 2002-01-17 2016-05-18 Φαρμακευτικες συνθεσεις που περιλαμβανουν βαλσαρτανη και αναστολεις nep

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20071101386T CY1106959T1 (el) 2002-01-17 2007-10-25 Φαρμακευτικες συνθεσεις που περιλαμβανουν βαλσαρτανη και αναστολεις nep

Country Status (29)

Country Link
EP (1) EP1467728B1 (el)
JP (2) JP4820056B2 (el)
KR (2) KR100984939B1 (el)
CN (2) CN1615134A (el)
AT (1) ATE370732T1 (el)
AU (1) AU2003206738C1 (el)
BE (1) BE2016C025I2 (el)
BR (2) BR122018015003B8 (el)
CA (1) CA2472399C (el)
CO (1) CO5600999A2 (el)
CY (2) CY1106959T1 (el)
DE (1) DE60315795T2 (el)
DK (1) DK1467728T3 (el)
EC (1) ECSP045190A (el)
ES (1) ES2290429T3 (el)
FR (1) FR16C0019I2 (el)
HU (1) HUS1600024I1 (el)
IL (2) IL162661A0 (el)
LU (1) LU93074I2 (el)
MX (1) MXPA04006917A (el)
NL (1) NL300811I2 (el)
NO (2) NO333191B1 (el)
NZ (1) NZ533968A (el)
PL (1) PL212318B1 (el)
PT (1) PT1467728E (el)
RU (1) RU2334513C3 (el)
SI (1) SI1467728T1 (el)
WO (1) WO2003059345A1 (el)
ZA (1) ZA200405117B (el)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1776095A1 (en) * 2004-06-23 2007-04-25 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists
EA015108B1 (ru) 2004-12-24 2011-06-30 КРКА, д.д., НОВО МЕСТО Способ получения твердой фармацевтической композиции, содержащей валсартан
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (en) * 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
CZ300801B6 (cs) * 2006-06-07 2009-08-12 Helvetia Pharma A.S. Kompozice s valsartanem v pevných lékových formách
JP5715339B2 (ja) 2007-01-12 2015-05-07 ノバルティス アーゲー ５−ビフェニル−４−アミノ−２−メチルペンタン酸の製造方法
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
ES2536514T3 (es) * 2007-11-06 2015-05-26 Novartis Ag Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP)
CN101774941A (zh) 2009-01-13 2010-07-14 浙江九洲药业股份有限公司 2-酰基氨基-3-联苯基丙酸的制备及拆分方法
MX2011012627A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
EP2594557B1 (en) 2009-05-28 2016-08-10 Novartis AG Substituted aminopropionic derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
WO2012025501A1 (en) 2010-08-23 2012-03-01 Novartis Ag Process for the preparation of intermediates for the manufacture of nep inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
MA37850A1 (fr) * 2012-08-24 2018-07-31 Novartis Ag Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
CN105073762B (zh) 2013-02-14 2017-03-08 诺华股份有限公司 作为nep(中性内肽酶)抑制剂的取代的联苯丁酰膦酸衍生物
EA026989B1 (ru) 2013-02-14 2017-06-30 Новартис Аг Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью
CN104230865B (zh) * 2013-06-13 2018-01-09 上海翰森生物医药科技有限公司 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
US20160206597A1 (en) 2013-08-26 2016-07-21 Toni Lynne Bransford New Use
WO2015028941A1 (en) * 2013-08-26 2015-03-05 Novartis Ag New use
WO2016029828A1 (zh) * 2014-08-27 2016-03-03 上海翰森生物医药科技有限公司 AHU-377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
WO2016037098A1 (en) * 2014-09-04 2016-03-10 Concert Pharmaceuticals, Inc. Deuterated sacubitril
WO2016037552A1 (zh) * 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
CN105503760A (zh) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
DK3218351T3 (da) 2014-11-14 2019-09-16 Zentiva Ks Fremgangsmåde til fremstilling, isolering og oprensning af farmaceutisk anvendelige former af ahu-377
CN107074744B (zh) * 2014-12-03 2019-06-18 上海翰森生物医药科技有限公司 Nep抑制剂结晶型游离酸、钙盐多晶型及其制备方法和应用
MX2017007426A (es) * 2014-12-08 2018-04-20 Crystal Pharmatech Co Ltd Formas cristalinas de complejo supramolecular trisodico que comprende valsartan y ahu-377 y metodos de las mismas.
CN105693543B (zh) * 2014-12-15 2018-08-10 四川海思科制药有限公司 沙库比曲类衍生物、其药物组合物、制备方法及用途
CN104826115A (zh) * 2015-04-19 2015-08-12 浙江巨泰药业有限公司 一种抗心衰药物组合物及其制备方法
CN106138069A (zh) * 2015-04-21 2016-11-23 刘春丽 作为治疗来自非角化复层上皮组织的不适的局部药剂的1-二仲丁基膦酰基戊烷
HRP20230480T1 (hr) 2015-05-11 2023-07-21 Novartis Ag Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca
US20180140579A1 (en) 2015-05-29 2018-05-24 Novartis Ag Sacubitril and valsartan for treating metabolic disease
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
CN106389374A (zh) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 一种含有lcz696的药物组合物及其制备方法
JP6598985B2 (ja) 2015-08-28 2019-10-30 ノバルティス アーゲー 新規の使用
WO2017036420A1 (zh) * 2015-09-06 2017-03-09 常州方楠医药技术有限公司 含沙库比曲和缬沙坦的药用组合物及其制备方法
CN105348209B (zh) 2015-12-09 2017-12-26 浙江天宇药业股份有限公司 一种抗心衰药lcz696的制备方法
MX2018007129A (es) 2015-12-11 2018-11-09 Zentiva Ks Formas solidas de ester etilico del acido (2r,4s)-5-(bifenil-4-il) -4-[(3-carboxipropionil)amino]-2-metil-pentanoico, sus sales y un metodo de preparacion.
US20190054069A1 (en) 2016-02-03 2019-02-21 Novartis Ag New use of a combination of sacubitril and valsartan
US10722471B2 (en) 2016-02-03 2020-07-28 Novartis Ag Galenic formulations of organic compounds
EP3524250A4 (en) 2016-10-08 2020-05-20 Wuhan LL Science And Technology Development Co., Ltd. PHARMACEUTICAL COMPOSITION
WO2018211479A1 (en) 2017-05-19 2018-11-22 Lupin Limited Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
WO2019020706A1 (en) 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN110237071B (zh) 2018-03-09 2022-03-22 武汉朗来科技发展有限公司 药物制剂及其应用
US20210177803A1 (en) 2018-08-23 2021-06-17 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
WO2021158084A1 (ko) * 2020-02-07 2021-08-12 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
KR20210101164A (ko) 2020-02-07 2021-08-18 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
KR20200020746A (ko) 2020-02-07 2020-02-26 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
KR20210120560A (ko) 2020-03-27 2021-10-07 주식회사 유영제약 고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20220091767A (ko) 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1256692A (en) * 1991-02-06 1992-09-07 Schering Corporation Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
CA2168066A1 (en) * 1995-02-08 1996-08-09 James R. Powell Treatment of hypertension and congestive heart failure
WO2001074348A2 (en) * 2000-04-03 2001-10-11 Bristol-Myers Squibb Co. Vasopeptidase inhibitors to treat isolated systolic hypertension
WO2001097805A2 (en) * 2000-06-22 2001-12-27 Novartis Ag Solid valsartan pharmaceutical compositions
PL205715B1 (pl) * 2000-07-19 2010-05-31 Novartis Ag Sól wapniowa walsartanu w postaci tetrahydratu, preparat farmaceutyczny zawierający tę sól, zastosowanie i sposób wytwarzania tej soli
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives

Also Published As

Publication number Publication date
IL162661A (en) 2010-11-30
RU2334513C2 (ru) 2008-09-27
NO2016009I1 (no) 2016-05-18
BE2016C025I2 (el) 2022-05-17
CA2472399A1 (en) 2003-07-24
PT1467728E (pt) 2007-11-14
BR122018015003B1 (pt) 2018-11-21
SI1467728T1 (sl) 2008-02-29
JP2005514441A (ja) 2005-05-19
ZA200405117B (en) 2005-08-31
CY2016013I1 (el) 2016-10-05
BRPI0306907B1 (pt) 2018-10-30
BRPI0306907B8 (pt) 2021-05-25
NO2016009I2 (no) 2016-05-18
ES2290429T3 (es) 2008-02-16
BR0306907A (pt) 2004-12-21
CO5600999A2 (es) 2006-01-31
DE60315795D1 (de) 2007-10-04
CY1106959T1 (el) 2012-01-25
KR20040078127A (ko) 2004-09-08
ATE370732T1 (de) 2007-09-15
NO20043380L (no) 2004-10-07
AU2003206738A1 (en) 2003-07-30
IL162661A0 (en) 2005-11-20
ECSP045190A (es) 2004-08-27
CN1615134A (zh) 2005-05-11
PL369773A1 (en) 2005-05-02
CN102091330B (zh) 2015-04-08
BR122018015003B8 (pt) 2021-07-27
DE60315795T2 (de) 2008-06-05
JP4820056B2 (ja) 2011-11-24
NZ533968A (en) 2006-10-27
MXPA04006917A (es) 2004-12-06
EP1467728B1 (en) 2007-08-22
AU2003206738C1 (en) 2020-01-30
RU2004125178A (ru) 2005-06-10
JP2011207898A (ja) 2011-10-20
EP1467728A1 (en) 2004-10-20
FR16C0019I1 (el) 2016-06-24
WO2003059345A1 (en) 2003-07-24
NL300811I2 (el) 2016-07-27
HUS1600024I1 (hu) 2016-06-28
RU2334513C3 (ru) 2017-10-24
CA2472399C (en) 2012-02-21
CN102091330A (zh) 2011-06-15
LU93074I2 (fr) 2016-07-18
NO333191B1 (no) 2013-03-25
DK1467728T3 (da) 2007-12-27
AU2003206738B2 (en) 2006-12-21
KR20100057704A (ko) 2010-05-31
FR16C0019I2 (fr) 2017-12-08
PL212318B1 (pl) 2012-09-28
KR100984939B1 (ko) 2010-10-01

Similar Documents

Publication Publication Date Title
CY2016013I2 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν βαλσαρτανη και αναστολεις nep
CY2018009I2 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
NO20054789D0 (no) Sammensetninger inneholdende piperaciliin og tazobactam nytting for injeksjon
CY2014001I1 (el) Συνδυασμος αζελαστινης και φλουτικαζονης
CY2013043I1 (el) Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv
CY2014033I1 (el) Παραγωγα κινολινης και η χρηση τους ως μυκοβακτηριακων αναστολεων
EE05509B1 (et) Aktiveeritud polalkleenglkoolpolmeer ja seda sisaldavad kompositsioonid
IL173639A0 (en) Ppar-activating compound and pharmaceutical composition containing same
IS7948A (is) Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
ATE401800T1 (de) Hochintensive süssstoffzusammensetzung und deren abgabe
IL175252A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
DK1354873T3 (da) Perindoaprilsalt og farmaceutiske sammensætninger indeholdende dette
DK1425019T3 (da) Farmaceutisk sammensætning omfattende et androgen
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
FR2834693B1 (fr) Emballage presentoir
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
DK1587478T3 (da) Farmaceutisk sammensætning
IL176077A0 (en) 1-n-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them
PT1558263E (pt) Composicao farmaceutica de libertacao prolongada
DE60335143D1 (de) Mundpflegezusammensetzungen und -verfahren
DE60330764D1 (de) Pharmazeutische zusammensetzung enthaltend einen lipase - inhibitor und glucomannan
EP1541139A4 (en) DRUG COMPOSITION WITH NF-KAPPA B HEMMER
IS7581A (is) Lyfjasamsetning
NO20044164L (no) Farmasoytiske sammensetninger
FR2857939B1 (fr) Film d'emballage